Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial.

Ilse H van de Wijgert,Maaike G E Fenten,Akkie Rood,Regina L M van Boekel,Miranda L van Hooff,Kris C P Vissers
{"title":"Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial.","authors":"Ilse H van de Wijgert,Maaike G E Fenten,Akkie Rood,Regina L M van Boekel,Miranda L van Hooff,Kris C P Vissers","doi":"10.1213/ane.0000000000007611","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nPostoperative pain after lumbar spine surgery is often severe, necessitating multimodal analgesic regimens that include opioids. Locoregional anesthesia, such as the Erector Spinae Plane Block (ESPB), may be effective in reducing postoperative pain and opioid use. This study evaluated the effect of bilateral ESPB on early postoperative pain and opioid use after lumbar spinal fusion surgery.\r\n\r\nMETHODS\r\nA single-center, randomized, blinded, placebo-controlled trial included 76 patients undergoing elective lumbar spinal fusion. Participants received either bilateral ESPB with ropivacaine or placebo (normal saline) after surgery. The primary outcome was pain intensity 1-hour postanesthesia, measured using the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption in the first 12 hours, time to first opioid use, quality of recovery, and pain intensity and opioid use at 30 days. Statistical significance was set at P < .05.\r\n\r\nRESULTS\r\nThe mean NRS 1-hour postanesthesia did not differ significantly between the ropivacaine and placebo group (3.8 ± 3 vs 4. 2 ± 2.6, P = .56). The median 12-hour opioid consumption was 11.3mg [2.5-21.5] vs 12.5 mg [5.1-22.4], median time to first opioid use 64 [22-171.5] vs 41 [21.3-89.5] minutes, and mean quality of recovery on day 1: 90. 7 ± 36 vs 102. 8 ± 20.5 and day 3: 108. 3 ± 21.2 vs 112. 5 ± 22.7, for the ropivacaine and placebo group, respectively. At 30 days, the mean NRS was 3. 4 ± 2.4 vs 3. 6 ± 2.5. Opioid use at 30 days occurred in 12 patients (16.2%) of the ropivacaine and in 15 (20.3%) of the placebo group.\r\n\r\nCONCLUSIONS\r\nBilateral ESPB with ropivacaine did not reduce early postoperative pain or opioid use in patients undergoing lumbar spinal fusion. Its overall benefits in a multimodal analgesic regimen appear limited and application of bilateral ESPB in all patients undergoing lumbar spine surgery is not recommended.","PeriodicalId":7799,"journal":{"name":"Anesthesia & Analgesia","volume":"20 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesia & Analgesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1213/ane.0000000000007611","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Postoperative pain after lumbar spine surgery is often severe, necessitating multimodal analgesic regimens that include opioids. Locoregional anesthesia, such as the Erector Spinae Plane Block (ESPB), may be effective in reducing postoperative pain and opioid use. This study evaluated the effect of bilateral ESPB on early postoperative pain and opioid use after lumbar spinal fusion surgery. METHODS A single-center, randomized, blinded, placebo-controlled trial included 76 patients undergoing elective lumbar spinal fusion. Participants received either bilateral ESPB with ropivacaine or placebo (normal saline) after surgery. The primary outcome was pain intensity 1-hour postanesthesia, measured using the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption in the first 12 hours, time to first opioid use, quality of recovery, and pain intensity and opioid use at 30 days. Statistical significance was set at P < .05. RESULTS The mean NRS 1-hour postanesthesia did not differ significantly between the ropivacaine and placebo group (3.8 ± 3 vs 4. 2 ± 2.6, P = .56). The median 12-hour opioid consumption was 11.3mg [2.5-21.5] vs 12.5 mg [5.1-22.4], median time to first opioid use 64 [22-171.5] vs 41 [21.3-89.5] minutes, and mean quality of recovery on day 1: 90. 7 ± 36 vs 102. 8 ± 20.5 and day 3: 108. 3 ± 21.2 vs 112. 5 ± 22.7, for the ropivacaine and placebo group, respectively. At 30 days, the mean NRS was 3. 4 ± 2.4 vs 3. 6 ± 2.5. Opioid use at 30 days occurred in 12 patients (16.2%) of the ropivacaine and in 15 (20.3%) of the placebo group. CONCLUSIONS Bilateral ESPB with ropivacaine did not reduce early postoperative pain or opioid use in patients undergoing lumbar spinal fusion. Its overall benefits in a multimodal analgesic regimen appear limited and application of bilateral ESPB in all patients undergoing lumbar spine surgery is not recommended.
竖脊肌平面阻滞在腰椎融合术后多模式镇痛中的应用:一项盲法随机安慰剂对照试验。
背景:腰椎手术后疼痛通常很严重,需要包括阿片类药物在内的多模式镇痛方案。局部麻醉,如直立脊柱平面阻滞(ESPB),可能有效减少术后疼痛和阿片类药物的使用。本研究评估了双侧ESPB对腰椎融合术后早期疼痛和阿片类药物使用的影响。方法采用单中心、随机、盲法、安慰剂对照试验,纳入76例择期腰椎融合术患者。手术后,参与者接受双侧ESPB加罗哌卡因或安慰剂(生理盐水)。主要终点是麻醉后1小时的疼痛强度,使用数字评定量表(NRS)测量。次要结局包括前12小时的阿片类药物消耗、首次使用阿片类药物的时间、恢复质量、疼痛强度和30天的阿片类药物使用。差异有统计学意义,P < 0.05。结果罗哌卡因组和安慰剂组麻醉后1小时平均NRS无显著差异(3.8±3 vs 4)。2±2.6,p = 0.56)。12小时阿片类药物消耗中位数为11.3mg [2.5-21.5] vs 12.5 mg[5.1-22.4],首次使用阿片类药物的中位数时间为64 [22-171.5]vs 41[21.3-89.5]分钟,第1天的平均恢复质量为:90。7±36 vs 102。8±20.5,第三天:108。3±21.2 vs 112。罗哌卡因组5±22.7,安慰剂组5±22.7。30 d时,平均NRS为3。4±2.4 vs 3。6±2.5。罗哌卡因组的12名患者(16.2%)和安慰剂组的15名患者(20.3%)在30天内使用阿片类药物。结论双侧ESPB加罗哌卡因不能减少腰椎融合术患者术后早期疼痛或阿片类药物的使用。其在多模式镇痛方案中的总体益处似乎有限,不推荐在所有腰椎手术患者中应用双侧ESPB。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信